Next Article in Journal
The Importance of Endophenotypes to Evaluate the Relationship between Genotype and External Phenotype
Next Article in Special Issue
Exosomes: From Garbage Bins to Promising Therapeutic Targets
Previous Article in Journal
An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis
Previous Article in Special Issue
MicroRNAs: New Insight in Modulating Follicular Atresia: A Review
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2017, 18(2), 473; doi:10.3390/ijms18020473

Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer

Division of Clinical Oncology, Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, A-8036 Graz, Austria
Department of Orthopaedic and Trauma Surgery, Medical University of Graz, Auenbruggerplatz 5, A-8036 Graz, Austria
Department of Urology, Medical University of Graz, Auenbruggerplatz 5/6, A-8036 Graz, Austria
Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer, 1515 Holcombe Blvd., Houston, TX 77030, USA
Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA
Author to whom correspondence should be addressed.
Academic Editor: Constantinos Stathopoulos
Received: 16 January 2017 / Revised: 9 February 2017 / Accepted: 16 February 2017 / Published: 22 February 2017
(This article belongs to the Collection Regulation by Non-Coding RNAs)
View Full-Text   |   Download PDF [496 KB, uploaded 22 February 2017]   |  


The importance of long non-coding RNAs (lncRNAs) in the pathogenesis of various malignancies has been uncovered over the last few years. Their dysregulation often contributes to or is a result of tumour progression. In prostate cancer, the most common malignancy in men, lncRNAs can promote castration resistance, cell proliferation, invasion, and metastatic spread. Expression patterns of lncRNAs often change during tumour progression; their expression levels may constantly rise (e.g., HOX transcript antisense RNA, HOTAIR), or steadily decrease (e.g., downregulated RNA in cancer, DRAIC). In prostate cancer, lncRNAs likewise have diagnostic (e.g., prostate cancer antigen 3, PCA3), prognostic (e.g., second chromosome locus associated with prostate-1, SChLAP1), and predictive (e.g., metastasis-associated lung adenocarcinoma transcript-1, MALAT-1) functions. Considering their dynamic role in prostate cancer, lncRNAs may also serve as therapeutic targets, helping to prevent development of castration resistance, maintain stable disease, and prohibit metastatic spread. View Full-Text
Keywords: long non-coding RNAs; prostate cancer; carcinogenesis long non-coding RNAs; prostate cancer; carcinogenesis

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Smolle, M.A.; Bauernhofer, T.; Pummer, K.; Calin, G.A.; Pichler, M. Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer. Int. J. Mol. Sci. 2017, 18, 473.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top